Grant number: | 16/24019-0 |
Support Opportunities: | Regular Research Grants |
Start date: | May 01, 2017 |
End date: | April 30, 2019 |
Field of knowledge: | Health Sciences - Dentistry |
Principal Investigator: | Estela Kaminagakura Tango |
Grantee: | Estela Kaminagakura Tango |
Host Institution: | Instituto de Ciência e Tecnologia (ICT). Universidade Estadual Paulista (UNESP). Campus de São José dos Campos. São José dos Campos , SP, Brazil |
Associated researchers: | Alfredo Ribeiro da Silva ; Cláudia Malheiros Coutinho Camillo ; Jorge Esquiche León ; Román Carlos |
Abstract
Introduction: Laryngeal papillomatosis is a benign neoplasia divided into two groups: juvenile and adult laryngeal papillomatosis. It is caused by the human papillomavirus (HPV). HPV types 6 and 11 are related to its etiology; however, the possible viral co-infection has been suggested in lesions of the head and neck region. Objectives: To describe the clinical and microscopic characteristics of juvenile and adult laryngeal papillomatosis; to genotype HPVs and comparing them with samples from Guatemala and Brazil, to investigate the presence of EBV-DNA by polymerase chain reaction (PCR) and EBV-RNA by in situ hybridization (ISH); to validate the presence of EBV through the immunoexpression of CD21, and to correlate the clinical-pathological results with the clinical and laryngoscopic scale by Derkay et al., 1998. Materials and Methods: 80 juvenile papillomatosis of paraffin blocks will be retrospectively reviewed through the slides of H&E. They will subdivided into 2 groups: low and high malignization risk based on Derkay index. The presence of HPV DNA in these specimens will be analyzed by polymerase chain reaction (PCR) using SPF10 primers (gene L1), it will be performed the hybridization of DNA strands for HPV genotyping. The DNA-EBV investigation will be performed through PCR for primers for the BamH1W segment. In situ hybridization for EBV-RNA (EBER) will be performed. The validation of the results for EBV will be realized by immunohistochemical reaction against-CD21. Clinical-pathological and molecular characteristics will be compared between groups using the Chi-square test or Fisher's exact test with a significance level of 5%. (AU)
Articles published in Agência FAPESP Newsletter about the research grant: |
More itemsLess items |
TITULO |
Articles published in other media outlets ( ): |
More itemsLess items |
VEICULO: TITULO (DATA) |
VEICULO: TITULO (DATA) |